The new fast-acting insulin ‘Lyumjev’ can now be prescribed at general hospitals in Korea.

According to industry sources, Lilly Korea’s ‘Lyumjev (insulin lispro)’ has passed the drug committee (DC) reviews of various medical institutions including the Samsung Medical Center.

Lyumjev, which was approved in Korea in December last year, has been approved for reimbursement since September this year. Its prescriptions are expected to begin in earnest after landing in more general hospitals.

As mealtime insulin, Lyumjev contains the active ingredient ‘insulin lispro-aabt,’ and is used to help reduce blood sugar levels in adults with type 1 or type 2 diabetes who have dif